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Abstract
Dystrophin (Dmd) is a structural protein that links the extracellular matrix to actin filaments
in muscle fibers and is required for the maintenance of muscles integrity. Mutations in Dmd
lead to muscular dystrophies in humans and other vertebrates. Here, we report the charac-
terization of a zebrafish gene trap line that fluorescently labels the endogenous Dmd protein
(Dmd-citrine,Gt(dmd-citrine) ct90a). We show that the Dmd-citrine line recapitulates endoge-
nous dmd transcript expression and Dmd protein localization. Using this Dmd-citrine line,
we follow Dmd localization to the myosepta in real-time using time-lapse microscopy, and
find that the accumulation of Dmd protein at the transverse myosepta coincides with the
onset of myotome formation, a critical stage in muscle maturation. We observed that Dmd
protein localizes specifically to the myosepta prior to dmdmRNA localization. Additionally,
we demonstrate that the Dmd-citrine line can be used to assess muscular dystrophy follow-
ing both genetic and physical disruptions of the muscle.
Introduction
Dystrophin (Dmd) is an essential structural protein in the Dystrophin Associated Protein
Complex (DAPC) of skeletal muscles that links the extracellular matrix to the cytoskeletal actin
filaments of the myofibril [1, 2]. Mutations in components of the DAPC result in muscular dys-
trophy, a condition characterized by progressive muscle weakness and degeneration. Dmd mu-
tations are the cause of approximately 90% of all human forms of muscular dystrophies. In
particular, DMD is the gene that is mutated in most cases of Becker Muscular Dystrophy and
Duchenne Muscular Dystrophy (BMD and DMD, respectively) [3–6]. DMD is an X-linked
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recessive, fatal disorder. It has been estimated that 1 in 3,500 to 5,000 boys suffers from
DMD [7, 8], and that approximately three to six of every 100,000 live births are affected by
BMD [9, 10].
Several vertebrate models have been developed to study DMD [11], ranging from mdx mice
[12, 13] and dystrophic golden retriever dogs [14], to DMD-deficient cats [15], and mutant
zebrafish [16–18]. Several zebrafish alleles of dmdmutations were identified by the Tubingen
screen [16], including dmdtm90c, dmdta222a and dmdtj7. Twelve additional alleles have been
identified and referenced by the Zebrafish Mutation Project conducted at the Sanger Institute
[19]. The dystrophin-deficient zebrafish dmdta222a (Sapjemutant) has a nonsense mutation in
exon 4 of dmd [17]. The Sapje-likemutant was isolated more recently, and carries a dmd splice
site mutation within exon 62 [18]. The Sapje and Sapje-like alleles recapitulate the muscle de-
generation phenotypes observed in humans [17, 18], providing a good model for the study of
muscular dystrophies [20]. These genetic models have provided many insights into the molecu-
lar lesions that can lead to muscular dystrophy; however, real-time monitoring of Dmd expres-
sion and localization in vivo, in order to assess both wildtype muscle development and
progression of muscle dystrophy at the cellular and protein level, remains a challenge. The
challenge results, in part, from the large size of Dmd, a 427 KDa protein that is encoded by 79
exons [21, 22]. The Dmd protein is composed of four major domains: 1) an actin-binding N-
terminal domain, 2) a large array of 24 spectrin-repeats that form triple-helical coiled coils, 3) a
cysteine-rich domain composed of EF-hands and a ZZ zinc finger motif and 4) a C-terminal
domain that binds components of the DAPC [23, 24]. In addition, four proline-rich hinge do-
mains link the spectrin-repeats in the Dmd protein. These hinge domains have been shown to
influence muscle maturation and maintenance, as well as the structures of the myotendinous
junction and of the neuromuscular synapses [25]. This modular organization of the Dmd pro-
tein into large, well-conserved protein domains suggests that a compact insertion, such as a
fluorescent protein, might be added by genetic engineering without disrupting the function of
Dmd.
Immunocytochemical localization of Dmd protein in skeletal muscles shows a reproducible
progression with development. In humans, Dmd protein is initially detected in the cytoplasm
of skeletal muscles, but it is later localized to the plasma membrane after 10 weeks of gestation
[26, 27], and is localized mainly at the neuromuscular junction upon birth. It has long been
suggested that different isoforms account for the differential localizations of Dmd, as different
staining patterns have been observed using different antibodies against specific domains of
Dmd [27]. The differential localization of Dmd can be recapitulated in primary muscle cell cul-
tures, as Dmd is detected in the sarcoplasm during early myoblast fusion, and at the cell mem-
brane in more differentiated myotubes [28]. In zebrafish embryos, Dmd protein has been
reported to be localized to the myosepta [18, 29–35]. In adult zebrafish there is a shift in Dmd
localization (starting around 7 days post fertilization) to a more widespread sarcolemmal ex-
pression [36, 37] and to the muscle cell membranes [37].
Vertebrate skeletal muscle arises from the paraxial mesoderm, which becomes segmented
into the repeated structure of the somites, forming sequentially in an anterior to posterior pat-
tern (reviewed in [38]). In zebrafish, the first pair of somites is formed at 10.5 hours post-
fertilization (hpf). The next 5 pairs appear every 20 minutes thereafter, followed by the remain-
ing 24 pairs every 30 minutes at 28.5°C [39, 40]. Each somite is separated from its rostral and
caudal neighbors by a sheet of extracellular matrix, the vertical myoseptum, and each somite is
divided into dorsal and ventral muscle masses by another sheet of matrix that forms the hori-
zontal myoseptum. The muscle fibers that arise from each somite are thought to use the myo-
septa for attachment. Dmd appears to play a role in this attachment [17], as failure of these
attachments to form during the development of sapjemutant embryos, results in muscular
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dystrophy phenotypes [41]. Although multiple studies demonstrate that Dmd is an important
player in muscle development, structure, maintenance and signaling, all analyses of Dmd local-
ization have been based on fixed specimens. For example, in the live imaging study of muscle
fiber attachment in Sapjemutants [35], the Dmd protein dynamics could not be assessed. As
muscular dystrophy is a progressive disorder, the ability to follow Dmd and the progression of
the disease in real time would be informative; however, there has been no animal model with a
fluorescently tagged Dmd protein that would permit such studies.
Here, we characterize a gene trap line in which full-length Dmd is fused to the fluorescent
protein Citrine (Gt(dmd-citrine)ct90a). We demonstrate that the fusion protein (Dmd-citrine)
and transcript (dmd-citrine) recapitulate the endogenous expression of the Dmd protein and
transcript. Interestingly, we observe a spatial difference of dmd transcript localization during
development that is not reflected at the protein level. Real-time analysis in Gt(dmd-citrine)ct90a
embryos show that, unlike its transcript, Dmd protein is expressed at the myosepta as soon as
it is detected, and this protein localization becomes more defined and sharper as the skeletal
muscle develops. Finally, we illustrate that the Gt(dmd-citrine)ct90a line can be used to assess
muscle phenotypes in vivo.
Materials and Methods
Zebrafish
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the California Institute of Technology. The protocol
was approved by the Institutional Animal Care and Use Committee (IACUC) of the California
Institute of Technology (Permit Number: 1227). Wild-type embryos were obtained from AB
and TL strains. Gt(dmd-citrine)ct90a transgenic embryos were obtained from a screen per-
formed in the laboratory [42]. Adult fish were maintained as described in [43].
RNA injections and morpholino experiments
For RNA microinjection, 2.3nL of a 50ng/μL mRNA encoding for membrane-mCherry and
H2B-cerulean were injected into 1-cell stage embryos. The plasmids used were pCS-H2B-
cerulean and pCS-membrane-mCherry [44]. They were linearized with NotI, purified using a
Qiagen nucleotide removal spin column and used as template for in vitro transcription with
the Ambion Message Machine kit (Life Technology, catalogue #AM1340). Gt(dmd-citrine)ct90a
zebrafish embryos were injected at the 1-cell stage with 10ng of dmdmorpholino antisense oli-
gonucleotide (dmd AS2 morpholino from [45], sequence: 5'-TTGAGTCCTTTAATCCTACAA
TTTT-3’) or 10ng of inverted dmd morpholino / control morpholino (AS2 inverted from
[45], sequence: 5'- TTTTAACATCCTAATTTCCTGAGTT-3’). Morpholinos were diluted fol-
lowing manufacturer instructions (Gene Tools). Embryos were then raised, at 28.5°C, to the de-
sired stage for analysis.
Immunohistochemistry
Embryos were raised to the stage required, dechorionated, and anesthetised in 0.01% tricaine
before being fixed in 4% Paraformaldehyde (PFA). Following fixation, embryos were pre-
incubated in Phosphate Buffered Saline (PBS) with DMSO and Triton (PBDT; 1X PBS, 0.1%
Triton-100, 1% Bovine Serum Albumin (BSA), 1% DMSO) for 1h at room temperature. Incu-
bation with the primary antibody was performed overnight at 1:200 dilution in PBDT, followed
by washing and incubation with a secondary Alexa- coupled antibody (546nm, Invitrogen) for
4h at room temperature (RT) in PBDT. Primary antibodies used were: anti-Dmd (Mandra-1,
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Developmental Studies Hybridoma Bank (DSHB)), anti-Myosin heavy chain fast isoforms
(F59, DSHB), anti-Myosin heavy chain slow muscle fibres (S58, DSHB), anti-Tropomyosin
(CH1, DSHB), anti-Laminin (Sigma, catalogue #L9393), and anti-GFP to recognize Citrine
(Torrey Pines Biolabs, catalogue #TP-401).
Imaging, reconstructions and analysis
Imaging was performed on a Zeiss LSM510 inverted confocal microscope. Embryos were placed
into agarose moulds [44] and imaged with the following lasers: 514nm to excite Citrine; 543nm
to excite Bodipy-TR, Alexa-546 and membrane-mCherry; 458nm to excite H2B-cerulean. Im-
ages were taken using a water-immersion 40X 1.1NA Apochromat objective using the Zeiss
LSM software and time-lapse imaging was performed using the Zeiss multi-time macro. To per-
mit accurate comparisons, all embryos in a given experiment were imaged using the same laser
power, gain detector settings and scanning speed. For live imaging, BODIPY-TR (Life Technol-
ogy, catalogue #C34556) was used as a counterstain. 3D reconstructions and projections were
performed using Imaris 6.4 (Bitplane). Custom written codes in MATLAB 2013b were used to
quantify the number of pixels and their intensities. The kymograph was generated by assigning
all the pixels of a given time point one single color.
Chromogenic in situ hybridization (ISH)
Chromogenic ISHs were performed and imaged as described in [46]. A digoxigenin (DIG)
probe was synthesized using a plasmid template that contained a 2Kb fragment of the 3’ end of
the dmd gene. Embryos were dechorionated and fixed in 4% PFA overnight at 4°C before being
dehydrated in a series of methanol and phosphate buffered saline with Tween (PBST; 1X PBS,
0.1% Tween-20). Proteinase K was used to permeabilize embryos before washing and pre-
hybridized at 70°C for 1h. Hybridization was performed overnight at 70°C and DIG probe was
detected with 1:5,000 anti-DIG alkaline phosphatase. Stained embryos were imaged with both
wide-field and confocal microscopes. To improve the 3D localization and resolution of the
ISHs, we used the technique described by Trinh and colleagues [46] to detect the far-red fluo-
rescence of the NBT/BCIP chromogenic stain using a 510 LSM Zeiss confocal microscope.
Western-blotting
Batches of 20 embryos (72 hpf) were dechorionated and pooled together per condition in egg
water (0.6g/L aquarium salt in water, 0.01mg/L methylene blue) and 0.01% Tricaine. Anesthe-
tized embryos were de-yolked in calcium-free Ringer’s solution (116mMNaCl, 2.9mM KCl,
5mMHEPES pH 7.2), rinsed two times in fresh calcium-free Ringer’s solution before being put
into Tris buffer saline with NP40 (1% NP40, 150mMNaCl, 50mM Tris-HCl pH8) with anti-
proteases (Roche, Complete Mini, catalogue #04693159001). After 30 minutes on ice and vor-
texing, the samples were centrifuged at top speed for 15 minutes at 4°C. The supernatant was
collected and used for Western blotting. Standard Western-blotting techniques were followed
using gradient 4–15% Tris-Acetate gels (Bio-Rad). Membranes were incubated in primary anti-
body, followed by washing and incubating in anti-mouse-conjugated goat horseradish peroxi-
dase (HRP) secondary antibody (1: 10,000). Dmd was detected using the Mandra-1 antibody
(DSHB, 1:1,000) and Tubulin using anti-alpha Tubulin, clone DM1A (Sigma, 1:3,000). We de-
tected a single band at greater than 180kDa in the Westerns, indicating that this antibody may
not detect all isoforms of Dmd. The blots were finally incubated in Western Lightning Chemi-
luminescence Reagent (Perkin Elmer), as suggested by the manufacturer, and exposed to film.
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Heat-shock treatment
Batches of 20 6-somite stage Gt(dmd-citrine)ct90a embryos were dechorionated and pooled to-
gether in 0.5mL egg water (0.6g/L aquarium salt in water, 0.01mg/L methylene blue) in an
Eppendorf tube, before being subjected to heat-shock at 40°C for 30 minutes in a water bath.
After heat-shock treatment, embryos were placed into 28.5°C egg water and incubated until
morphological and molecular assessments could be performed. Control Gt(dmd-citrine)ct90a
embryos were kept at 28.5°C for the entire time as a comparison.
In situ Hybridization Chain Reaction (HCR)
20 25-mer probes were designed against exon 2 of the dmdmRNA; seven 25mer probes were
used for the detection of tropomyosin 3, and six for the detection of citrine (sequences provided
in supplemental information). In situHCR was performed as described in [47, 48]. Briefly, zeb-
rafish embryos were fixed in 4% PFA overnight at 4°C, followed by washing in PBS and a series
of dehydrations and rehydrations in methanol and PBST. Pre-hybridization was done in 50%
hybridization buffer (HB; 50% formamide, 2X Saline Sodium Citrate (SSC), 9mM citric acid,
0.1% Tween-20, 500 μg/mL tRNA and 50 μg/mL Heparin) for 30min at 55°C. Hybridization
was performed overnight in 50% HB with 6pmol of each probe at 55°C. The next day the speci-
mens were washed in a series of 50% HB and 2X SSC, followed by a series of 2X SSC (300mM
NaCl, 30mM Na3Citrate-2H20) and PBST washes. The samples were pre-hybridized in 40%
HB (40% formamide, 2X SSC, 9mM citric acid pH6, 0.5% Tween 20, 2.5 mg/mL tRNA, 250 ug/
mL Heparin) for 30min at 45°C and the fluorescently labelled hairpins were snap-cooled before
use. After overnight incubation at 45°C with the hairpins, the embryos were washed and
mounted for imaging. For counterstaining of the nuclei, 1ug/mL of DAPI in PBS was added to
samples after in HCR reaction was completed and allowed to incubate at room temperature for
1hr before imaging.
Results
Identification of a gene trap in the dmd locus
From a gene trap screen in which the Tol2-based FlipTrap vector was randomly integrated into
the zebrafish genome, we isolated a line (ct90aGT) that exhibited expression in the developing
muscle (Fig 1b–1e). The FlipTrap vector contains an internal exon encoding a variant of yellow
fluorescent protein, citrine [42]. When integrated into the intron of actively expressed genes,
citrine is transcribed as an artificial exon to create a fusion transcript with the trapped locus.
Translation of the trapped transcript leads to expression of a full-length Citrine fusion protein
(Fig 1a). In the ct90aGT line, the Citrine fusion protein expression is visible starting at 18 hpf, by
wide-field and confocal microscopy, in the somite boundaries (Fig 1b–1e). This expression in-
creases over developmental time as indicated by an increase in Citrine fluorescence (Fig 1b–1e).
By 6dpf, Citrine fusion protein expression was detected in all skeletal muscle including cranial
muscles (Fig 1d and 1e).
Molecular analysis by 3’ Rapid Amplification of cDNA Ends (3’-RACE) with primers
against the citrine sequence [42] revealed that the FlipTrap vector inserted between exons 4
and 5 of the dystrophin (dmd) locus (Fig 1a). Both exons 4 and 5 are in phase zero, as is the arti-
ficial citrine exon, creating an in-frame fusion protein. Protein domain prediction suggests
that the gene trap creates a fusion protein with Citrine between the two CH domains in the N-
terminal calponin homology domain of Dmd (Fig 1a), and would not be expected to disrupt
the function of Dmd. Consistent with this prediction, Gt(dmd-citrine)ct90a homozygous indi-
viduals are viable and do not exhibit muscular dystrophy as would be expected if the insertion
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Fig 1. FlipTrapGt(dmd-citrine)ct90a line allows visualization of Dmd protein. (a). Schematic of the FlipTrap vector inserted within dmd locus. Citrine
insertion (green) occurs within intron 4–5 in dmd in theGt(dmd-citrine)ct90a trap line (top) and upon translation produces a fluorescently tagged full-length
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in dmd were mutagenic [41]. Gt(dmd-citrine)ct90a homozygous individuals are viable into
adulthood and show no noticeable morphological or behavioral phenotypes that have been in-
dicative of mutations in dmd such as swimming defects. Western blot analysis indicates that
the Dmd-citrine fusion protein is expressed as a single protein, approximately 30 KDa larger
than the Dmd protein, consistent with the citrine exon’s predicted molecular mass of 30 KDa.
While multiple isoforms have been documented for Dmd [49], our data suggest that the gene
trap insertion leads to a single isoform being tagged in the ct90aGT line.
Gt(dmd-citrine)ct90a recapitulates endogenous Dmd protein expression
Expression and co-localization analyses indicate that the Gt(dmd-citrine)ct90a line recapitulates
the expression and localization of endogenous Dmd protein. First, subcellular localization anal-
ysis of Dmd-citrine in ct90aGT embryos by co-expression of membrane (membrane-mCherry)
and nuclear (H2B-cerulean) labels reveal that Dmd-citrine localizes to the myoseptal junctions
at the sarcoplasmic side of the sarcolemma, and is excluded from the interior of the muscle
cells (Fig 2a). Second, co-localization analysis by antibody staining for proteins expressed in
the either muscle fibers or myosepta indicate that Dmd-citrine co-localizes with myoseptal
components (Fig 2b–2e). Myosin heavy chain and Tropomyosin are expressed in the muscle fi-
bers while Laminin localizes to the extracellular matrix of the myosepta [50, 51]. Antibody co-
localization experiments performed on these proteins in ct90aGT embryos show that Dmd-
citrine localizes to the myosepta, similar to Laminin (Fig 2e). Finally, immunohistochemistry
with antibodies performed on endogenous Dmd and Citrine in ct90aGT embryos show that
Dmd and Dmd-citrine colocalize (Fig 2b). The colocalization between Dmd and Dmd-citrine
can be detected at the myoseptum starting at 18-19somite, suggesting that there is no difference
in the maturation time of Dmd and Dmd-citrine protein. Collectively, these results show that
the Gt(dmd-citrine)ct90a line accurately reflects Dmd expression in zebrafish embryos.
Temporal differences in the localization of dmd transcript and Dmd
protein during somite development
Dmd transcript has been reported to be spatially distinct in both mature and developing mus-
cles. In human skeletal muscles, dmd transcripts are localized preferentially to the sub-sarco-
lemma of muscle cells, both in normal and DMD/BMD patients [52]. In contrast, in
developing zebrafish muscle, dmdmRNA is initially detected throughout the cytoplasm of
myoblasts and localizes to the transverse myosepta by 24hpf [32, 36, 53]. To assess the localiza-
tion of dmdmRNA and determine if the dmd-citrine transcript recapitulates the endogenous
localization of dmd, we employed in situHybridization Chain Reaction (HCR) [48] to simulta-
neously detect dmd and dmd-citrine transcripts in ct90aGT embryos. The dmdHCR probes
bind to both dmd and dmd-citrine transcripts, while the citrine probes bind only to dmd-citrine
transcripts (Fig 3a–3n). Using this combination of probes, we found that dmd and dmd-citrine
fusion transcripts both localize predominantly to the transverse myosepta in 48hpf embryos
(Fig 3g–3i and 3l–3n). Additionally, dmd and dmd-citrine probes localize as dots in the nuclei
suggesting that the HCR probes are labeling nascent transcripts (Fig 3i, 3j and 3n–3o). The cit-
rine probe labels a single dot in heterozygous ct90aGT embryos and two dots in homozygous
embryos; the dmd probe labels two dots in all embryos (Fig 3i and 3n inset, Fig 3j and 3o, S1
functional Dmd protein (bottom). The exons (blue rectangles), introns (blank line) and domains of the protein are not drawn to scale. (b-e). Wide-field
fluorescent images of Dmd-Citrine expression in theGt(dmd-citrine)ct90a line, in the trunk skeletal muscles (b-c) at 24hpf (b) and 32hpf (c); (d-e). Expression
in the cranial skeletal muscle at 6dpf (lateral (d) and ventral (e) views). Ventral view showing expression in the skeletal muscle of the branchial arches. Scale
bars: (b)-(c) 100μm, (d)-(e) 25μm.
doi:10.1371/journal.pone.0128944.g001
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Fig 2. TheGt(dmd-citrine)ct90a trap line recapitulates endogenous Dmd protein expression. (a). Single optical section confocal images of live 30hpf
ct90aGT embryo show that Dmd-citrine fusion protein is localized at the somite border. Dmd is in green (citrine), nuclei are in blue (H2B-cerulean), and
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Fig). These data are consistent with heterozygous ct90aGT embryos having a single copy of the
gene trap and homozygous ct90aGT embryos having two copies. More importantly, the dmd
and citrine probes show colocalization at the myosepta and in the nuclei in homozygous em-
bryos indicating that dmd-citrine recapitulates dmd transcript localization.
To further characterize the localization of dmd transcript, we performed a time-course of
dmd expression using chromogenic in situ hybridization. Assessing the expression of dmd in
one hour developmental time intervals starting at 19.5 hpf, we found that dmd transcript
switches from a non-localized diffused pattern in the cytoplasm of the muscle cells at 21.5hpf,
to a restricted pattern at the transverse myosepta at 22.5 hpf (Fig 4a–4d), where it remains
throughout development. The same switch from a diffused to localized pattern is observed
when detecting dmd transcript by HCR in situ hybridization (S2 Fig), with the exception that
in situHCR also detects the nuclear dots in all developmental stages.
The differential distribution of dmd transcript led us to ask whether dmd protein exhibits a
similar change in localization during development. To assess mRNA and protein in the same
sample, we performed in situHCR to detect dmd transcript followed by immunohistochemis-
try to detect Dmd protein with an antibody to Citrine (Fig 4e–4l). This dual detection approach
revealed that Dmd protein is restricted to the myosepta from the onset of Dmd protein expres-
sion, at 18 hpf, when dmd transcript is diffusely dispersed in the cytoplasm (Fig 4e–4h). By 26
hpf both dmd transcript and protein are localized to the myosepta with nascent dmd transcripts
detected as small dots in nuclei of muscle fibers (Fig 4i–4l)).
Dynamics of Dmd protein localization during somitogenesis
The Citrine fluorescent signature in the ct90aGT line enables real-time analysis of Dmd locali-
zation during somitogenesis (Fig 5a–5h); S3 Fig, S1 Movie). Dmd-citrine could be detected at
low levels in the somite boundaries starting at 18–18.5 hpf (Fig 5a and 5e). The expression in-
creases in intensity from the anterior to posterior somites (Fig 5a–5h). In vertebrates, the so-
matic muscles develop from the paraxial mesoderm in an anterior-to-posterior wave. In
zebrafish, this anterior-to-posterior developmental pattern initiates after gastrulation (12 hpf)
during which dmd transcripts have been detected [36]. However, we detect Dmd-citrine pro-
tein localization at the somite boundaries 6 hours after transcripts can be detected, at 18 hpf,
indicating that there is a significant delay between transcriptional active and
protein maturation.
To quantify the spatio-temporal dynamics of Dmd-citrine expression, we mapped the pixel
intensity of the fluorescence signal over time (Fig 5i–5l). Kymographs of the Dmd-citrine ex-
pression show that the Dmd-citrine protein shifts in space over time (Fig 5l). However, fluores-
cent images indicate that Dmd-citrine expression remains at the myoseptum (Fig 5a–5h)
suggesting that the shift in space may be due to movement of the tissue or growth of the em-
bryo. The shift in Dmd-citrine expression is unlikely due to an increase in the overall size of
the somites, as the width of each somite remains constant and the distance between each myo-
septum remains the same (Fig 5a–5l). The shift in Dmd-citrine protein expression is accompa-
nied by an increase in the total area in which Dmd-citrine can be detected in each developing
somite (Fig 5i, 5k and 5l), indicating that more Dmd-citrine proteins are accumulating at the
membranes are in red (membrane-mCherry mRNA injected). (b). Antibody staining for Citrine and endogenous Dmd in the trap line confirms their co-
localization at the somite border. Anti-Citrine label is in green and anti-Dmd label is in red. (c-f). Antibody staining for Citrine and endogenous muscle
proteins. Myosin heavy chain (c) and Tropomyosin (d) are expressed in the muscle fibers while Laminin (e) localizes to the extracellular matrix of the
myosepta. Scale bar = 10μm (a), 20μm (b).
doi:10.1371/journal.pone.0128944.g002
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Fig 3. TheGt(dmd-citrine)ct90a trap line enables visualizing differential expression in homozygous and heterozygous embryos via in situ HCR. (a,
f, k) Schematic of in situ HCR experiment showing dmd and citrineHCR probe binding sites within dmd and dmd-citrine transcript. The dmd HCR probe
should bind to both dmd and dmd-citrine transcripts, while citrineHCR probe binds only to dmd-citrine transcript. (b-e, g-j, l-o). in situ HCR analysis of dmd
(blue) and dmd-citrine (green) transcript in wild type (b-e), heterozygous (g-j) and homozygous (l-o)Gt(dmd-citrine)ct90a embryos. Tmp3 transcripts counter-
stain muscles in red. Insets in (d),(i) and (n) show zoomed in view of transcription sites in the nuclei. Two dots are detected in homozygous embryos (k-n)
whereas only one dot is detected in the nuclei of heterozygous ct90aGT embryos (f-i) while no citrine dots are detected in wild types embryos (a-d),
consistent with the copy number of citrine inserted in the respective embryos. (e, j, o) Magnified images of the three types of embryos with nuclei stained in
DAPI and the transcripts indicated by arrowheads. Scale bar (b-d, g-i, l-n)20μm (e,j,o)10μm.
doi:10.1371/journal.pone.0128944.g003
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myoseptum over time. To quantify the relative levels of Dmd-citrine in time, we mapped the
fluorescent intensity from the time-lapse analysis. We find that the relative mean pixel intensity
increases over developmental time, indicating that more fluorescent signal can be detected per
unit area (Fig 5k). Additionally, more pixels have fluorescent signature over developmental
time (Fig 5l), indicating that as the somites mature more Dmd-citrine proteins are localizing to
the myosepta.
Using theGt(dmd-citrine)ct90a line for phenotyping muscular dystrophy
The ability to detect Dmd protein in vivo enables the use of the Gt(dmd-citrine)ct90a line to as-
sess muscle phenotypes. First, we asked how morpholino anti-sense knockdown of Dmd
would affect Dmd-citrine expression in ct90aGT embryos. Injection of a previously published
ATG morpholino against dmd [45] resulted in a significant decrease in the amount of Dmd-
citrine fluorescence detected in ct90aGT embryos (Fig 6a and 6b) compared to control. The de-
crease in Dmd-citrine fluorescence correlated with a reduction of Dmd protein detected by
Western-blot (Fig 6c). In addition, ct90aGTmorpholino knockdown embryos exhibited dys-
trophy phenotype in which the muscles fibers are disorganized, the sarcolemma borders are
not precisely defined and the muscle fibers vary in size (data not shown).
In addition to morpholino knockdown, we asked whether the ct90aGT line could be used to
assess other muscular dystrophy phenotypes. Heat-shocks given during somitogenesis have
been shown to result in somite abnormalities, with defects appearing later than the given treat-
ment and not affecting somite formation at the time of the shock [54–56]. We performed heat-
Fig 4. dmdmRNA and Dmd protein expression show differences in spatial expression. (a-d). Chromogenic in situ hybridization for dmd in wild type
embryos at 18hpf (a,b) and 22hpf (c,d). (a,c) Wide field image of 18hpf and 22hpf embryos stained for dmd expression. (b,d) 3D projections of confocal z-
stack of embryos in (a) and (c), respectively. Fluorescent signal of NBT/BCIP stain for dmd transcript reveals spatial confinement of transcript between
somites. (e-p). Confocal image of dmd-citrine transcript (f,j,n) detected by in situHCR and antibody staining for DMD-citrine protein (e,i,m) inGt(dmd-
citrine)ct90a (e-l) and wildtype (m-p) embryos at 18hpf and 26hpf. Counter-stain with antibody to Ctnnb1 in blue (g,k,o). (h,l,p) Merged of image of (e-g, i-k, and
m-o). Comparison of protein and transcript expression at 18hpf (e-h) and 26 hpf (i-l) inGt(dmd-citrine)ct90a embryos show that DMD protein localize
exclusively to the myosepta while dmd-citrinemRNA is expressed in the cytoplasm at 18hpf and becomes more localized to the myosepta at 26hpf. Dmd-
citrine expression in the nucleus can be seen as dots that appear similar in distribution between 18hpf and 26hpf. (m-p) DMD-citrine protein (m) and transcript
(n) are not detected in wildtype embryos. Anti-Citrine antibody staining is in green, citrinemRNAHCR is in red and anti-Ctnnb1 antibody is in blue. Scale bars
(a) 50μm (b,m) 20 μm.
doi:10.1371/journal.pone.0128944.g004
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shock on ct90aGT embryos to determine the affects of heat-shock on Dmd-citrine expression.
Performing a single 30-minute heat-shock treatment in 6-somite stage (12 hpf) embryos from
the Gt(dmd-citrine)ct90a line resulted skeletal muscle defects between somites 16–25 at 32 hpf
(Fig 6d–6i). In the defective somites, disorganized muscle fibers are accompanied by an absence
of Dmd-citrine localization at the myoseptum (Fig 6g and 6i). This phenotype is consistent
with Dmd-citrine role as structural protein important linking the skeletal muscle to the
extracellular matrix.
Discussion
We describe a zebrafish gene trap line, Gt(dmd-citrine)ct90a that expresses a Dmd-citrine pro-
tein fusion allowing the dynamic study of muscular dystrophy. We have shown that the expres-
sion of Dmd-citrine in these embryos recapitulates endogenous Dmd protein and mRNA
localization. The tagging of Dmd with citrine did not seem to affect the interaction of Dmd
Fig 5. Dmd Protein expression increases both in intensity and area over development. (a-h). 3D projections of confocal Z-stacks images in developing
trunk ofGt(dmd-citrine)ct90a embryos from the 20 to 26 somites stages (19–22 hpf), showing expression of Dmd-citrine (a-d, green) and the vital stain
BodipyTRmethyl ester (e-h, red) from dorsal and lateral view. (i-l) Quantitation of Dmd-citrine fluorescent signal in confocal time-lapse. (i). Kymograph of
Dmd-citrine expression color-coded according to developmental stage. The spatial shift in expression appears to be due to tissue growth and expression
enhancement over time. (j). Histogram of fluorescent pixel intensities color-coded according to developmental stage with intensity in X-axis and frequency in
Y-axis. Plot shows Dmd-citrine expression increasing over time resulting in shift slope along the X-axis (blue to red). The inset shows the same plotted on a
log scale to enhance observation. (k). Mean pixel intensity plotted against development stage showing increase in fluorescent intensity of Dmd-citrine as
development progresses. The error bars denote the variation among all the pixels at that particular stage. (l). Total pixel count of Dmd-citrine fluorescent
plotted against developmental time showing that Dmd-citrine expression increase in spatial area over time. Scale bar = 20μm.
doi:10.1371/journal.pone.0128944.g005
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with its DAPC partners. Defects in protein interactions within the DAPC would have lead to
dystrophic phenotypes, and we did not observe any phenotypes in homozygous Gt(dmd-
citrine)ct90a embryos. This transgenic line enables spatio-temporal study of Dmd dynamics in a
live vertebrate animal model.
dmd transcript has been described to exhibit spatial differences in localization during devel-
opment. We have found that dmd transcript transitions from a cytoplasmic localization in the
myoblast to a discrete localization pattern in the myoseptum between 21.5 hpf and 22.5 hpf
(Fig 4(a)–4(d)). This transition in localization pattern coincides with a developmental stage
when myoblasts fuse to form myotubes [57]. The syncytial nature of the myotubes may allow
dmd transcripts to be discretely localized to the myoseptum. In the individual myoblast, the
cell membrane may serve as a physical barrier for localization to the myosepta. Consistent with
this hypothesis, we observe localization of dmd transcript in the myoseptum in 21.5 hpf embry-
os when cytoplasmic dmd transcript could be detected, indicating that localization of the tran-
script can occur at these earlier stages in development.
Quantitative analysis of the time-lapse data shows that not only does the mean signal inten-
sity of Dmd-citrine increase (by ~ 45%) as development proceeds but the total expression area
near the myoseptum increases as indicated by a 40% increase in the total number of pixels (Fig
5l). These results suggest that, as the myoblasts transitions to syncytial fibers, more Dystrophin
is recruited to the myosepta. The accumulation of Dmd to the myosepta, as the muscle fibers
Fig 6. Phenotyping of muscular dystrophy withGt(dmd-citrine)ct90a. (a,b). Dmd-citrine expression in control (a) and dmdmorphants (b). Embryos in (a)
and (b) were imaged with the same laser power and gain settings. (c) Western-blot of protein extracts fromWT (lanes 1, 2) andGt(dmd-citrine)ct90a (lanes 3,
4) embryos with antibody to DMD and tubulin (loading control). Embryos for protein extracts were injected with control morpholino (lanes 1 and 3) and dmd
morpholino (lanes 2 and 4, n = 3–6). Arrows point to size difference between Dmd and Dmd-citrine. (d,e) Widefield fluorescent image of 32hpf ct90aGT
embryos untreated (d) and treated with heat-shocked at 6-somites stage. Arrow point to defects in Dmd-citrine expression visible between somites 16–25. (f-
i) Heat-shocked embryos stained for Dmd (f,g; green) and anti-MHC (h,i; red) at 32hpf. Scale bars (d,e) 50μm (f-i) 20 μm.
doi:10.1371/journal.pone.0128944.g006
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mature, hints towards its importance in providing the mechanical anchoring for contracting
muscle. Consistent with a role in anchoring muscle fibers, morpholino knockdown of Dmd
show a progressive loss of Dmd-citrine expression and defects in muscle integrity. Additional-
ly, heat shock experiments that result in discrete muscle integrity defects between somites 15–
25 also results in lost of Dmd-citrine localization at these disrupted somites.
Interestingly we found that, during early zebrafish embryo development, dmdmRNA tran-
scripts first appeared diffused in the cytoplasm before being localized at the myosepta. We did
not observe such a differential pattern for Dmd protein. Dmd-citrine is initially detected at the
myoseptum between the 18–19 somite stages prior to the localization of the mRNA at the myo-
septum. This temporal difference in the localization of the mRNA and protein to the myosepta
suggests that DMD-citrine is translated or matures into detectable fluorescence at the myosep-
tum. Immunohistochemistry with antibodies to Dmd suggests that the temporal maturation of
Dmd and Dmd-citrine are similar as both proteins are detected at the myoseptum starting at
the 18–19 somite stage. At this stage cell fusion should be completed in the anterior somites,
but is not yet complete in the posterior somites [58]. Consistent with this anterior to posterior
wave of maturation of the somites, we observe a similar anterior to posterior wave of localiza-
tion of Dmd-citrine to the myoseptum in the time-lapse microscopy (Fig 5, S4 movie).
As development progresses, we see significant decrease in cytoplasmic distribution of dmd
transcript over 4 hours from 18hpf to 22hpf. In situHCR shows the nascent transcript sites in
the nucleus with nearly no localization of dmd-citrine or dmdmRNA in the cytoplasm by
26hpf when most of the myoblasts have completed fusion (Fig 4, S2 Fig). There is a possibility
that Dmd protein is present in the cytoplasm at levels below our detection limit; however, our
data indicate that the majority of the Dmd protein are localized to the myosepta. Previous
work on dynamics of mRNA-protein (mRNP) nucleocytoplasmic transport in mammalian
cells has shown that the cytoplasmic diffusion coefficient of dystophin mRNAs is low [59]. It
would be of interest to assess the dynamics of Dmd protein that is predicted to be slower given
it’s large size (427 KDa protein). Therefore increasing localization of the transcript itself at the
myoseptal junctions might facilitate effective translation or maturation of Dmd-citrine into de-
tectable fluorescence at the site of its activity. This localization might be helpful in bypassing
the time required for protein diffusion from the cytoplasm of fusing myoblasts or mature myo-
tomes to the somite boundaries, thereby making the availability of Dystrophin, for anchoring,
limited only by the rate of on-site translation. The ct90aGT line provides opportunities for fu-
ture studies to test these hypotheses.
Supporting Information
S1 Fig. Co-localization of dmd and dmd-citrine transcript in Gt(dmd-citrine)ct90a embryos
via in situHCR. (a-c) in situHCR of dmd (red), citrine (green) and tpm3 in Gt(dmd-
citrine)ct90a embryos. Tpm3 labels the cytoplasm of the myocytes while both dmd and citrine
are detected at the myosepta and in the nucleus. Dmd and citrine transcripts show overlap ex-
pression at the myosepta. (d) Merge of (a-c).
(EPS)
S2 Fig. Differential localization of dmd transcript over developmental time as detected via
in situHCR. (a) in situHCR of dmd-citrine (red) in ct90aGT embryos counter-stained for
tpm3 (blue). tpm3 Counter-stain show the nuclei by negative contrast. Inset shows zoomed in
view of active transcription sites in the nuclei. (b-d) 3D projections of confocal z-stacks of dmd
transcripts stained by in situHCR at 21hpf (b), 22hpf (c), and 25hpf (d). dmd transcript transi-
tions from the entire somite to the somite boundaries as development progresses.
(EPS)
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S3 Fig. Time lapse imaging of Dmd-citrine expression in Gt(dmd-citrine)ct90a trap line. 3D
projections of confocal Z-stacks images in developing trunk of Gt(dmd-citrine)ct90a embryos
from the 18 to 35 hpf, showing expression of Dmd-citrine (green) and the vitalstain BodipyTR
methyl ester (red) from dorsal view. The expression of Dmd-Citrinefusion (green) increases
with development. The microscope gain has been kept high inorder to detect citrine expression
as early as possible. Images taken from frames withinSupplemental movie 1. Scale bar = 20μm
(EPS)
S1 Movie. Time-lapse of Dmd-citrine. Time-lapse movie from confocal z-stack projections of
Dmd-citrine (green) expression inGt(dmd-citrine)ct90a embryo stained with BodipyTR methyl
ester from 18 to 35 hpf. Dorsal view image.
(MOV)
S1 Text. Methods.
(DOCX)
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